PAM50-based ROR indexes as a tool to individualize the use of neoadjuvant endocrine therapy in ER+/HER2-breast cancer

被引：0
|
作者：
Lopez Velazco, J. I. [1 ]
Manzano, S. [1 ]
Elorriaga, K. [2 ]
Lahuerta Martinez, A. [3 ]
Alvarez, L. A. [4 ]
Etxabe Azkue, I. [4 ]
Huarte Martinez, M. [4 ]
Buch, E. [5 ]
Gimenez Climent, J. [6 ]
Quiroga Garcia, V. [7 ]
Aragon, S. [8 ]
Pare, L. [9 ]
Prat, A. [10 ]
Alvarez Lopez, I. [11 ,12 ]
Munoz Caffarel, M. [13 ,14 ]
Urruticoechea, A. [11 ,12 ]
机构：
[1] Biodonostia Hlth Res Inst, Dept Oncol, San Sebastian, Spain
[2] OSIDonostialdea Onkol, Pathol Unit, Gipuzkoa Pathol Unit, San Sebastian, Spain
[3] OSI Donostialdea Onkol, Dept Oncol, Gipuzkoa Canc Unit, San Sebastian, Spain
[4] General Surg Gynecol & Gen Surg Dept, Breast Unit, Onkol, San Sebastian, Spain
[5] Hosp Sagunto Hosp Clin Univ, Dept Oncol, Valencia, Spain
[6] Valencia Oncol Inst IVO, Dept Oncol, Valencia, Spain
[7] ICO Inst Catala Oncol Badalona Hosp Univ Germ, Dept Oncol, Badalona, Spain
[8] Hosp 12 Octubre, Dept Oncol, Madrid, Spain
[9] Hosp Clin Barcelona, Oncol Dept, Barcelona, Spain
[10] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[11] Biodonostia Hlth Res Inst, Dept Oncol, San Sebastian, Spain
[12] OSI Donostialdea Onkol, Gipuzkoa Canc Unit, San Sebastian, Spain
[13] Biodonostia Hlth Res Inst, Oncol Dept, Bilbao, Spain
[14] Ikerbasque, Basque Fdn Sci, Bilbao, Spain
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
96P
引用
收藏
页码：S168 / S169
页数：2
相关论文
共 50 条
  • [1] Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2-breast cancer
    Ragusi, Max A. A.
    Winter-Warnars, Gonneke A. O.
    Wesseling, Jelle
    Linn, Sabine C.
    Beets-Tan, Regina G.
    van der Velden, Bas H. M.
    Elias, Sjoerd G.
    Gilhuijs, Kenneth G. A.
    Loo, Claudette E.
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1123):
  • [2] TILs in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Viale, G.
    Curigliano, G.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 3 - 3
  • [3] Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2-breast cancer
    Dodaran, Maryam Soleimani
    Borgoni, Simone
    Sofyali, Emre
    Verschure, Pernette J.
    Wiemann, Stefan
    Moerland, Perry D.
    van Kampen, Antoine H. C.
    [J]. BMC CANCER, 2020, 20 (01)
  • [4] MRI Patterns in the evaluation of pathological response after Neoadjuvant Endocrine therapy in ER+/HER2-Breast Cancer and Implications on Surgical Planning
    Nakad, B.
    Milevsky, D.
    Simovici, P.
    Brodsky, A.
    [J]. BREAST, 2023, 68 : S57 - S58
  • [5] Targeting of endocrine therapy-induced estrogen-receptor/HER2-cross-talk in circulating tumor cells from metastatic ER+/HER2-breast cancer: Implications for treatment of ER+/HER2-breast cancer
    Thaler, S.
    Rosswag, S.
    Pantel, K.
    Sleeman, J. P.
    Schmidt, M.
    Cotarelo, C. L.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [6] Estetrol for treatment of advanced ER+/HER2-breast cancer
    Schmidt, Marcus
    Hoenig, Arnd
    Zimmerman, Yvette
    Verhoeven, Carole
    Almstedt, Katrin
    Battista, Marco
    Lenhard, Hans Georg
    Krijgh, Jan
    Bennink, Herjan Coelingh
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [7] Early metabolic response assessment to neoadjuvant endocrine treatment in ER+, HER2-breast cancer: comparison to the morphological and pathological response
    Boughdad, Sarah
    Champion, Laurence
    Becette, Veronique
    Cherel, Pascal
    Mouret-Fourme, Emmanuelle
    Edeline, Veronique
    Lemonnier, Jerome
    Lerebours, Florence
    Alberini, Jean-Louis
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03):
  • [8] Everolimus plus endocrine vs endocrine therapy in treatment advanced ER+, HER2-breast cancer patients: A meta-analysis
    Wang, Na
    Wang, Kai
    Liu, Ya-ting
    Song, Fei-xue
    [J]. CURRENT PROBLEMS IN CANCER, 2019, 43 (02) : 106 - 114
  • [9] Hormone receptor alterations and treatment responses after neoadjuvant therapy in patients with ER+/HER2-breast cancer.
    Maeda, Shigeto
    Tohyama, Hiroaki
    Tokai, Yukiko
    Nakashima, Kazuaki
    Kamohara, Yukio
    Nagata, Yasuhiro
    Ito, Masahiro
    Fujioka, Hikaru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2-Breast Cancer
    Oshi, Masanori
    Takahashi, Hideo
    Tokumaru, Yoshihisa
    Yan, Li
    Rashid, Omar M.
    Nagahashi, Masayuki
    Matsuyama, Ryusei
    Endo, Itaru
    Takabe, Kazuaki
    [J]. CELLS, 2020, 9 (07) : 1 - 19
12345